PMC Articles for MedGen (Select 409522) - PMC

Links from MedGen

Items: 1 to 20 of 33

<< First< Prev

Page of 2

Select item 109615971.

Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study

Côme De Metz, Benjamin Hennart, Estelle Aymes, Pierre‐Yves Cren, Niels Martignène, Nicolas Penel, Maël Barthoulot, Aurélien Carnot

Cancer Med. 2024 Mar; 13(6): e7066. Published online 2024 Mar 25. doi: 10.1002/cam4.7066

PMCID:: PMC10961597

Article PDF–324K

Select item 104967672.

Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based adjuvant chemotherapy for colon cancer

Gabriel A. Brooks, Stephanie Tapp, Allan T. Daly, Jonathan A. Busam, Anna N.A. Tosteson

Clin Colorectal Cancer. Author manuscript; available in PMC 2023 Sep 12.

Published in final edited form as: Clin Colorectal Cancer. 2022 Sep; 21(3): e189–e195. Published online 2022 May 11. doi: 10.1016/j.clcc.2022.05.001

PMCID:: PMC10496767

Article PDF–564K

Select item 102980943.

Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy

Javier Guijarro-Eguinoa, Sara Arjona-Hernandez, Stefan Stewart, Olga Pernia, Pedro Arias, Itsaso Losantos-García, Tania Rubio, Miranda Burdiel, Carlos Rodriguez-Antolin, Patricia Cruz-Castellanos, Oliver Higuera, Alberto M. Borobia, Sonia Rodriguez-Novoa, Javier de Castro-Carpeño, Inmaculada Ibanez de Caceres, Rocio Rosas-Alonso

Int J Mol Sci. 2023 Jun; 24(12): 9843. Published online 2023 Jun 7. doi: 10.3390/ijms24129843

PMCID:: PMC10298094

Article PDF–839K

Select item 102655964.

Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping

B. Royer, M. Launay, J. Ciccolini, L. Derain, F. Parant, F. Thomas, J. Guitton

ESMO Open. 2023 Jun; 8(3): 101577. Published online 2023 May 31. doi: 10.1016/j.esmoop.2023.101577

PMCID:: PMC10265596

Article PDF–498K

Select item 101631575.

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe

M. de With, A. Sadlon, E. Cecchin, V. Haufroid, F. Thomas, M. Joerger, R.H.N. van Schaik, R.H.J. Mathijssen, C.R. Largiadèr, ‘The Working Group on the Implementation of DPD-deficiency Testing in Europe’

ESMO Open. 2023 Apr; 8(2): 101197. Published online 2023 Mar 28. doi: 10.1016/j.esmoop.2023.101197

PMCID:: PMC10163157

Article PDF–5.2M

Select item 100920896.

Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency

Maud Maillard, Manon Launay, Bernard Royer, Jérôme Guitton, Elodie Gautier‐Veyret, Sophie Broutin, Camille Tron, Félicien Le Louedec, Joseph Ciccolini, Damien Richard, Hugo Alarcan, Vincent Haufroid, Naïma Tafzi, Antonin Schmitt, Marie‐Christine Etienne‐Grimaldi, Céline Narjoz, Fabienne Thomas, the Groupe de Pharmacologie Clinique Oncologique (GPCO)

Br J Clin Pharmacol. 2023 Feb; 89(2): 762–772. Published online 2022 Oct 3. doi: 10.1111/bcp.15536

PMCID:: PMC10092089

Article PDF–1.4M

Select item 100241417.

Implementation and clinical benefit of DPYD genotyping in a Danish cancer population

N.H. Paulsen, P. Pfeiffer, M. Ewertz, P.B.N. Fruekilde, S. Feddersen, H.S. Holm, T.K. Bergmann, C. Qvortrup, P. Damkier

ESMO Open. 2023 Feb; 8(1): 100782. Published online 2023 Feb 13. doi: 10.1016/j.esmoop.2023.100782

PMCID:: PMC10024141

Article PDF–726K

Select item 99399988.

Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia

Hatouf H. Sukkarieh, Turki AlSagoor, Mohammed Alnuhait, Rami Bustami, Scott Bryson, Fatima Mohammed Kebir Adem, Hana Abdalla, Gulsan Karbani

Cancer Rep (Hoboken) 2023 Feb; 6(2): e1704. Published online 2022 Aug 14. doi: 10.1002/cnr2.1704

PMCID:: PMC9939998

Article PDF–901K

Select item 98576859.

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation

Theodore J. Wigle, Samantha Medwid, Cameron Ross, Ute I. Schwarz, Richard B. Kim

Curr Oncol. 2023 Jan; 30(1): 663–672. Published online 2023 Jan 4. doi: 10.3390/curroncol30010051

PMCID:: PMC9857685

Article PDF–427K

Select item 982641110.

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview

Niels Herluf Paulsen, Fie Vojdeman, Stig Ejdrup Andersen, Troels K. Bergmann, Marianne Ewertz, Peter Plomgaard, Morten Rix Hansen, Peter Skov Esbech, Per Pfeiffer, Camilla Qvortrup, Per Damkier

Basic Clin Pharmacol Toxicol. 2022 Nov; 131(5): 325–346. Published online 2022 Sep 8. doi: 10.1111/bcpt.13782

PMCID:: PMC9826411

Article PDF–1.5M

Select item 974956511.

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity

Charlotte W Ockeloen, Aron Raaijmakers, Manon Hijmans-van der Vegt, Jörgen Bierau, Judith de Vos-Geelen, Annelieke ECAB Willemsen, Bianca JC van den Bosch, Marieke JH Coenen

J Oncol Pharm Pract. 2023 Jan; 29(1): 5–13. Published online 2021 Nov 19. doi: 10.1177/10781552211049144

PMCID:: PMC9749565

Article PDF–689K

Select item 969473312.

Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays

Ottavia De Luca, Gerardo Salerno, Donatella De Bernardini, Maria Simona Torre, Maurizio Simmaco, Luana Lionetto, Giovanna Gentile, Marina Borro

Int J Mol Sci. 2022 Nov; 23(22): 13923. Published online 2022 Nov 11. doi: 10.3390/ijms232213923

PMCID:: PMC9694733

Article PDF–1.3M

Select item 932233913.

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study

Mirjam de With, Jonathan Knikman, Femke M. de Man, Carin A. T. C. Lunenburg, Linda M. Henricks, André B. P. van Kuilenburg, Jan G. Maring, Maurice C. van Staveren, Niels de Vries, Hilde Rosing, Jos H. Beijnen, Dick Pluim, Anil Modak, Alex L. T. Imholz, Ron H. N. van Schaik, Jan H. M. Schellens, Hans Gelderblom, Annemieke Cats, Henk‐Jan Guchelaar, Ron H. J. Mathijssen, Jesse J. Swen, Didier Meulendijks

Clin Pharmacol Ther. 2022 Jul; 112(1): 62–68. Published online 2022 May 4. doi: 10.1002/cpt.2608

PMCID:: PMC9322339

Article PDF–892K

Select item 919130214.

Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy

Kyoin Koo, Amy L. Pasternak, N. Lynn Henry, Vaibhav Sahai, Daniel L. Hertz

JCO Oncol Pract. 2022 Jun; 18(6): e958–e965. Published online 2022 Mar 3. doi: 10.1200/OP.21.00874

PMCID:: PMC9191302

Article PDF–376K

Select item 912290815.

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine

Shigehiro Tsukahara, Masaki Shiota, Dai Takamatsu, Shohei Nagakawa, Takashi Matsumoto, Ryo Kiyokoba, Mikako Yagi, Daiki Setoyama, Nozomi Noda, Shinya Matsumoto, Tetsutaro Hayashi, Alberto Contreras-Sanz, Peter C. Black, Junichi Inokuchi, Kenichi Kohashi, Yoshinao Oda, Takeshi Uchiumi, Masatoshi Eto, Dongchon Kang

Sci Rep. 2022; 12: 8535. Published online 2022 May 20. doi: 10.1038/s41598-022-12528-3

PMCID:: PMC9122908

Article PDF–2.9M

Select item 909911716.

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase

Jihyun Kang, Andrew HyoungJin Kim, Inseung Jeon, Jaeseong Oh, In‐Jin Jang, SeungHwan Lee, Joo‐Youn Cho

Clin Transl Sci. 2022 May; 15(5): 1104–1111. Published online 2021 Dec 4. doi: 10.1111/cts.13203

PMCID:: PMC9099117

Article PDF–1.7M

Select item 888555817.

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

P. García-Alfonso, M. Saiz-Rodríguez, R. Mondéjar, J. Salazar, D. Páez, A. M. Borobia, M. J. Safont, I. García-García, R. Colomer, X. García-González, M. J. Herrero, L. A. López-Fernández, F. Abad-Santos

Clin Transl Oncol. 2022; 24(3): 483–494. Published online 2021 Nov 13. doi: 10.1007/s12094-021-02708-4

PMCID:: PMC8885558

Article PDF–926K

Select item 838230418.

DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment

Ontario Health (Quality)

Ont Health Technol Assess Ser. 2021; 21(14): 1–186. Published online 2021 Aug 12.

PMCID:: PMC8382304

Article PDF–2.6M

Select item 826453119.

How I treat stage II colon cancer patients

J. Taieb, M. Karoui, D. Basile

ESMO Open. 2021 Aug; 6(4): 100184. Published online 2021 Jul 5. doi: 10.1016/j.esmoop.2021.100184

PMCID:: PMC8264531

Article PDF–289K

Select item 809512520.

Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature

K. Hodroj, D. Barthelemy, J.-C. Lega, G. Grenet, M.-C. Gagnieu, T. Walter, J. Guitton, L. Payen-Gay

ESMO Open. 2021 Jun; 6(3): 100125. Published online 2021 Apr 23. doi: 10.1016/j.esmoop.2021.100125

PMCID:: PMC8095125

Article PDF–436K

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to:

Links from MedGen

Items: 1 to 20 of 33

Display Settings:

Send to:

Supplemental Content

Find related data

Recent activity